Passive transfer of nut allergy after liver transplantation

Department of Clinical Immunology, Royal Prince Alfred Hospital, Missenden Road, Camperdown, Sydney 2050, New South Wales, Australia.
Archives of Internal Medicine (Impact Factor: 13.25). 02/2003; 163(2):237-9. DOI: 10.1001/archinte.163.2.237
Source: PubMed

ABSTRACT An anaphylactic reaction to cashew nut developed in a nonatopic 60-year-old man 25 days after receiving a liver allograft from a 15-year-old atopic boy who died of anaphylaxis after peanut ingestion. The liver recipient had no history of nut allergy. Posttransplantation skin prick test results were positive for peanut, cashew nut, and sesame seed, and the donor had allergen-specific IgE antibodies to the same 3 allergens. Contact tracing of the recipients of other solid organs from the same donor disclosed no other development of allergic symptoms after ingestion of peanut or cashew nut. Results of molecular HLA typing did not detect any donor-origin leukocytes in the recipient after transplantation, which excluded peripheral microchimerism. The patient inadvertently ingested peanut-contaminated food and suffered a second anaphylactic reaction 32 weeks after the transplantation. This case illustrates that transfer of IgE-mediated hypersensitivity can occur after liver transplantation and have potentially serious consequences. We therefore recommend that organ donors undergo screening for allergies, and that recipients be advised regarding allergen avoidance.

  • [Show abstract] [Hide abstract]
    ABSTRACT: This parameter was developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology (JCAAI). The AAAAI and the ACAAI have jointly accepted responsibility for establishing "Food Allergy: A practice parameter update-2014." This is a complete and comprehensive document at the current time. The medical environment is a changing one, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, ACAAI, and JCAAI. These parameters are not designed for use by pharmaceutical companies in drug promotion.
    Journal of Allergy and Clinical Immunology 08/2014; DOI:10.1016/j.jaci.2014.05.013 · 11.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 32-year-old female received a combined pancreas and kidney transplantation from an 11-year-old boy following his death from a fatal peanut ingestion. The recipient had no prior history of allergy to peanuts. Circulating specific IgE levels against peanut and recombinant peanut allergens (Arah1, Arah2) were measured in serum samples collected from the transplant recipient one month before transplantation in a stored specimen, and one, three and six months after transplantation. Skin tests were also performed one, three and six months following transplantation. The patient's pre-transplant peanut IgE levels were negative. At one month post-transplant, the patient had a positive 6mm skin test to peanut and had an elevated serum IgE blood level to peanut, Arah1, Arah2 of 0.79kU/L, 0.47kU/L and 0.25kU/L respectively. At three months, the skin test diameter and the IgE to peanut, Arah1, Arah2 decreased to 4mm, 0.69kU/L, 0.18kU/L and <0.1kU/L respectively. At six months post-transplant, the patient's skin test and IgE level to peanuts became negative, (Tables 1,2). At that time, the patient underwent an oral peanut food challenge without evidence of a clinical reaction thus excluding a persistent peanut allergy. The patient received a total goal dose of seven grams of protein without immediate or delayed hypersensitivity. The patient has since reintroduced peanuts into her diet. The donor's other organs were tracked and the other recipient's reactions to peanuts were investigated. The liver recipient developed peanut anaphylaxis, while the solitary kidney recipient remained unsensitized to peanut. This article is protected by copyright. All rights reserved.
    Clinical & Experimental Allergy 06/2014; 44(8). DOI:10.1111/cea.12355 · 4.32 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Transplant-acquired allergy (TAA) was firstly described as transplant-acquired food allergy (TAFA) after bone marrow transplantations and mostly observed in a transient form. The picture is complicated by numerous case reports of TAFA after the receipt of liver grafts from donors with no documented history of food allergy. The estimated prevalence of TAFA among young children in the literature has been documented in various studies ranging from 6% to 57%. Although TAA is mostly found to be associated with liver transplantation; it has been recently reported to be related with heart, intestinal, lung and even renal transplantations in adults. Previous reviews of published cases of liver TAA misleadingly emphasized the predominance of children and the absence of TAA in cardiac, pulmonary, and renal transplant recipients. In different studies, the male/female ratio is equal. Literature data suggest that children with TAFA typically present within the first year after surgery and are typically allergic to multiple foods. The pathogenesis of TAA is not still completely understood. Most of the studies support the concept that the functioning liver itself, and not only tacrolimus immunosuppression, is one of the main contributors to TAA in these patients. In the light of recent findings, other possible mechanisms can be summarized as following: (1) the recovery of delayed type hypersensitivity; (2) late manifestation of food allergy; (3) intestinal injury as well as inhibition of cellular energy production by tacrolimus; and (4) transfer of food-specific IgE or lymphocytes. Thus, interplay between hematopoietic cells from the transplanted organ and recipient specific factors (e.g., younger age and atopic background) seem to underlie the development of TAA. Most patients will have symptomatic improvement following reduced immunosuppression and an appropriately restricted diet. Nevertheless, some studies suggest that atopic diseases occur in some of pediatric liver transplant recipients, with manifestations including food allergy, eczema, allergic rhinitis, and asthma. More studies would be needed including greater number of patients to determine whether TAA is transient or not in pediatric/adult solid organ recipients.
    09/2013; 3(3):30-35. DOI:10.5500/wjt.v3.i3.30